An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism

The purpose of this study is to investigate the safety and efficacy of memantine extended release, as well as its extent of absorption in pediatric patients with autism.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : Memantine - Extended Release (ER)
  • drug : Placebo

Phase: Phase 2

Eligibility

Ages Eligible For Study:

6 Years - 18 Years

Inclusion Criteria

- Males or females ages 6 to 12 years - Diagnosis of autistic disorder, according to DSM-IV-TR using Autism Diagnostic Interview-Revised and Autism Diagnostic Observation Schedule (modules 2 & 3). - A knowledgeable caregiver capable of providing reliable information about the patient's condition, able to attend all clinic visits with the patient - Patients over age 12, only if they completed Study MEM-PK-21

External Links

Explore related trials

Contact information

Primary Contact:

Robin Libove 6507361235

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: